$Celcuity(CELC)$
查了周末没啥特别消息，涨这么猛
Celcuity announced very strong topline results from its Phase 3 VIKTORIA-1 trial in HR⁺/HER2⁻, PIK3CA wild-type advanced breast cancer. Their lead drug candidate, gedatolisib (a pan-PI3K/mTOR inhibitor) showed a 76% reduction in disease progression or death risk for the triplet regimen (gedatolisib + palbociclib + fulvestrant) and a 67% reduction for the doublet reg